• Tadahisa Numakura, Koji Murakami, Tsutomu Tamada, Chiaki Yamaguchi, Chihiro Inoue, Shinya Ohkouchi, Naoki Tode, Hirohito Sano, Hiroyuki Aizawa, Kei Sato, Ayumi Mitsune, Hajime Kurosawa, Toru Nakazawa, and Hisatoshi Sugiura.
• Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan.
• Intern. Med. 2022 Oct 15; 61 (20): 310131063101-3106.

AbstractBNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.

19 keywords...

hide…